Cytomegalovirus Infections in Pediatric Liver Transplantation

Susan M. King*, Martin Petric, Ric Superina, Nancy Graham, Eve A. Roberts

*Corresponding author for this work

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

From 1986 to 1989, 26 consecutive pediatric liver transplant recipients were followed up at The Hospital for Sick Children, Toronto, Canada. The patients were reviewed to assess the incidence of infection with cytomegalovirus, the severity of disease, and the relationship of recipient and donor serostatus to cytomegalovirus disease. Overall, the incidence of infection was 54% (14/26). Over 90% of patients who were seropositive or whose donors were seropositive developed evidence of cytomegalovirus infection after transplantation. Forty-three percent (6/14) of those with cytomegalovirus infections developed severe, fatal cytomegalovirus disease, despite treatment with immunoglobulins and ganciclovir (Syntex Laboratories Inc, Palo Alto, Calif) or foscarnet sodium (Astra, Pharmaceutical Products Inc, Westborough, Mass). Of all posttransplant deaths, two thirds were associated with severe cytomegalovirus infection. Cytomegalovirus-related deaths occurred in three of four seronegative patients with seropositive donors and three of six seropositive patients with seropositive donors. Therefore, a seropositive donor appeared to be a major risk factor for severe cytomegalovirus disease.

Original languageEnglish (US)
Pages (from-to)1307-1310
Number of pages4
JournalAmerican Journal of Diseases of Children
Volume144
Issue number12
DOIs
StatePublished - Jan 1 1990

Fingerprint

Cytomegalovirus Infections
Liver Transplantation
Cytomegalovirus
Tissue Donors
Pediatrics
Foscarnet
Ganciclovir
Incidence
Canada
Immunoglobulins
Transplantation
Liver
Infection
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

King, Susan M. ; Petric, Martin ; Superina, Ric ; Graham, Nancy ; Roberts, Eve A. / Cytomegalovirus Infections in Pediatric Liver Transplantation. In: American Journal of Diseases of Children. 1990 ; Vol. 144, No. 12. pp. 1307-1310.
@article{e833840b2e904bdd84c24b4c05edc298,
title = "Cytomegalovirus Infections in Pediatric Liver Transplantation",
abstract = "From 1986 to 1989, 26 consecutive pediatric liver transplant recipients were followed up at The Hospital for Sick Children, Toronto, Canada. The patients were reviewed to assess the incidence of infection with cytomegalovirus, the severity of disease, and the relationship of recipient and donor serostatus to cytomegalovirus disease. Overall, the incidence of infection was 54{\%} (14/26). Over 90{\%} of patients who were seropositive or whose donors were seropositive developed evidence of cytomegalovirus infection after transplantation. Forty-three percent (6/14) of those with cytomegalovirus infections developed severe, fatal cytomegalovirus disease, despite treatment with immunoglobulins and ganciclovir (Syntex Laboratories Inc, Palo Alto, Calif) or foscarnet sodium (Astra, Pharmaceutical Products Inc, Westborough, Mass). Of all posttransplant deaths, two thirds were associated with severe cytomegalovirus infection. Cytomegalovirus-related deaths occurred in three of four seronegative patients with seropositive donors and three of six seropositive patients with seropositive donors. Therefore, a seropositive donor appeared to be a major risk factor for severe cytomegalovirus disease.",
author = "King, {Susan M.} and Martin Petric and Ric Superina and Nancy Graham and Roberts, {Eve A.}",
year = "1990",
month = "1",
day = "1",
doi = "10.1001/archpedi.1990.02150360029013",
language = "English (US)",
volume = "144",
pages = "1307--1310",
journal = "JAMA Pediatrics",
issn = "2168-6203",
publisher = "American Medical Association",
number = "12",

}

Cytomegalovirus Infections in Pediatric Liver Transplantation. / King, Susan M.; Petric, Martin; Superina, Ric; Graham, Nancy; Roberts, Eve A.

In: American Journal of Diseases of Children, Vol. 144, No. 12, 01.01.1990, p. 1307-1310.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cytomegalovirus Infections in Pediatric Liver Transplantation

AU - King, Susan M.

AU - Petric, Martin

AU - Superina, Ric

AU - Graham, Nancy

AU - Roberts, Eve A.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - From 1986 to 1989, 26 consecutive pediatric liver transplant recipients were followed up at The Hospital for Sick Children, Toronto, Canada. The patients were reviewed to assess the incidence of infection with cytomegalovirus, the severity of disease, and the relationship of recipient and donor serostatus to cytomegalovirus disease. Overall, the incidence of infection was 54% (14/26). Over 90% of patients who were seropositive or whose donors were seropositive developed evidence of cytomegalovirus infection after transplantation. Forty-three percent (6/14) of those with cytomegalovirus infections developed severe, fatal cytomegalovirus disease, despite treatment with immunoglobulins and ganciclovir (Syntex Laboratories Inc, Palo Alto, Calif) or foscarnet sodium (Astra, Pharmaceutical Products Inc, Westborough, Mass). Of all posttransplant deaths, two thirds were associated with severe cytomegalovirus infection. Cytomegalovirus-related deaths occurred in three of four seronegative patients with seropositive donors and three of six seropositive patients with seropositive donors. Therefore, a seropositive donor appeared to be a major risk factor for severe cytomegalovirus disease.

AB - From 1986 to 1989, 26 consecutive pediatric liver transplant recipients were followed up at The Hospital for Sick Children, Toronto, Canada. The patients were reviewed to assess the incidence of infection with cytomegalovirus, the severity of disease, and the relationship of recipient and donor serostatus to cytomegalovirus disease. Overall, the incidence of infection was 54% (14/26). Over 90% of patients who were seropositive or whose donors were seropositive developed evidence of cytomegalovirus infection after transplantation. Forty-three percent (6/14) of those with cytomegalovirus infections developed severe, fatal cytomegalovirus disease, despite treatment with immunoglobulins and ganciclovir (Syntex Laboratories Inc, Palo Alto, Calif) or foscarnet sodium (Astra, Pharmaceutical Products Inc, Westborough, Mass). Of all posttransplant deaths, two thirds were associated with severe cytomegalovirus infection. Cytomegalovirus-related deaths occurred in three of four seronegative patients with seropositive donors and three of six seropositive patients with seropositive donors. Therefore, a seropositive donor appeared to be a major risk factor for severe cytomegalovirus disease.

UR - http://www.scopus.com/inward/record.url?scp=0025675631&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025675631&partnerID=8YFLogxK

U2 - 10.1001/archpedi.1990.02150360029013

DO - 10.1001/archpedi.1990.02150360029013

M3 - Article

C2 - 2173888

AN - SCOPUS:0025675631

VL - 144

SP - 1307

EP - 1310

JO - JAMA Pediatrics

JF - JAMA Pediatrics

SN - 2168-6203

IS - 12

ER -